NCT02083211: Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma |
|
|
| Completed | 3 | 168 | RoW | mAb Nimotuzumab, Placebo | National Institute of Cancerología, Pisa S.A de C.V, National Heart Institute, Mexico | Cervical Cancer Recurrent or Persistent, Palliative Treatment, Monoclonal Antibody in Cervical Cancer Treatment | 05/14 | 06/14 | | |
